Gutierrez, J. A., Heizer, G. M., Jones, W. S., Rockhold, F. W., Mahaffey, K. W., Fowkes, F. G. R., … Patel, M. R. (2020). CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J, 229, 118–120. https://doi.org/10.1016/j.ahj.2020.07.017

Gutierrez, J Antonio, Gretchen M. Heizer, W Schuyler Jones, Frank W. Rockhold, Kenneth W. Mahaffey, F Gerry R. Fowkes, Jeffrey S. Berger, et al. “CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.” Am Heart J 229 (November 2020): 118–20. https://doi.org/10.1016/j.ahj.2020.07.017.

Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, et al. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 Nov;229:118–20.

Gutierrez, J. Antonio, et al. “CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.” Am Heart J, vol. 229, Nov. 2020, pp. 118–20. Pubmed, doi:10.1016/j.ahj.2020.07.017.

Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 Nov;229:118–120.